Neuroendocrine tumor treatment using mTOR inhibitors

Details for Australian Patent Application No. 2006314444 (hide)

Owner Novartis AG

Inventors Marks, Peter Wayne; Lebwohl, David

Agent Davies Collison Cave

Pub. Number AU-B-2006314444

PCT Pub. Number WO2007/057457

Priority 06120660.3 14.09.06 EP; 0523658.3 21.11.05 GB; 0601082.1 19.01.06 GB; 0607942.0 21.04.06 GB; 0602747.8 10.02.06 GB; 0609912.1 18.05.06 GB; 0609272.0 10.05.06 GB

Filing date 20 November 2006

Wipo publication date 24 May 2007

Acceptance publication date 26 August 2010

International Classifications

A61K 31/436 (2006.01)

A61P 35/00 (2006.01) Antineoplastic agents

A61P 35/04 (2006.01) Antineoplastic agents

Event Publications

5 June 2008 PCT application entered the National Phase

  PCT publication WO2007/057457 Priority application(s): WO2007/057457

26 August 2010 Application Accepted

  Published as AU-B-2006314444

23 December 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006314445-Catalytic process for the oligomerization of olefinic monomers

2006314430-Electrolytic cell with a heat exchanger